Retinal flat mounts containing the HVS were prepared as described in detail.
7,23,24 In brief, the eyes were enucleated and fixed in 4% PFA for 2 hours at 4°C. After the fixation, the cornea, lens, uvea, and sclera were removed. The remaining retina containing the posterior HVS were rinsed in PBS and placed in 100% methanol for 10 minutes at room temperature. The retinas then were placed in PBS containing 2% bovine or 10% swine serum and 1% Triton X-100 for 1 hour at room temperature. The retinas were removed, and radial cuts were made for the preparation of flat mounts. The retinas were flat mounted on glass slides in mounting medium (TA-030-FM, Mountant Permafluor; Lab Vision Corporation, Fremont, CA). A fluorescent microscope (BZ-9000; KEYENCE, Osaka, Japan) was used to examine the flat mounts.
In addition to the retinal flat mounts, cross-sections of the eyes were prepared. After removal of the paraffin, they were rehydrated and blocked. The samples then were incubated overnight in primary antibodies at 4°C and then in the secondary antibodies for 1 hour at room temperature. The periostin was made visible by a conventional avidin-biotin-peroxidase protocol with 3-amino-9-ethylcarbazole as the substrate. The slides were examined with a light microscope.
The primary antibodies were fluorescein-labeled isolectin B4 (1:150 dilution, FL-1201; Vector Laboratories, Burlingame, CA), periostin (2 ng/μL, AF2955; R&D Systems), αSMA (1:250 dilution, F3777; Sigma, St. Louis, MO), F4/80 (1:100 dilution, MCA497R; Serotec, Raleigh, NC), Iba-1 (1:500 dilution, 019-19,741; Wako Pure Chemical Industries, Osaka, Japan), CD31 (1:500 dilution, 550,274; BD Bioscience Pharmingen, San Diego, CA), and Ninjurin-1 (1:100 dilution, 610,776; BD Bioscience Pharmingen). The secondary antibodies were Alexa Fluor 488, 546, and 647 (1:1000 dilution; Molecular Probes, Eugene, OR).